Evergreen, a US radiopharmaceutical contract manufacturer, will provide US-based manufacturing for Precirix’ lead product candidate, CAM-H2. Precirix is a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology. Its CAM-H2 product candidate is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer.
Quinz’ life sciences team is proud to have supported Precirix in negotiating the underlying contractual framework ensuring a reliable supply for Precirix’ CAM-H2 product candidate in view of its ongoing clinical studies.
More information about the Precirix – Evergreen partnering can be found on the website of Precirix.
